KR20150075498A - Rumex crispus extract for allergic diseases and process for preparation thereof - Google Patents
Rumex crispus extract for allergic diseases and process for preparation thereof Download PDFInfo
- Publication number
- KR20150075498A KR20150075498A KR1020130163521A KR20130163521A KR20150075498A KR 20150075498 A KR20150075498 A KR 20150075498A KR 1020130163521 A KR1020130163521 A KR 1020130163521A KR 20130163521 A KR20130163521 A KR 20130163521A KR 20150075498 A KR20150075498 A KR 20150075498A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- secretion
- rumex crispus
- allergen
- blocking
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 26
- 235000021501 Rumex crispus Nutrition 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims description 11
- 240000004284 Rumex crispus Species 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 2
- 230000008569 process Effects 0.000 title description 2
- 230000028327 secretion Effects 0.000 claims abstract description 27
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 25
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 23
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- 230000007815 allergy Effects 0.000 claims abstract description 14
- 230000000903 blocking effect Effects 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 235000013376 functional food Nutrition 0.000 claims abstract description 4
- 230000036541 health Effects 0.000 claims abstract description 3
- 239000013566 allergen Substances 0.000 claims description 30
- 244000207667 Rumex vesicarius Species 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 235000008504 concentrate Nutrition 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 239000012675 alcoholic extract Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 229940119485 safflower extract Drugs 0.000 claims description 2
- 241000218657 Picea Species 0.000 claims 2
- 235000015422 Rumex crispus ssp. crispus Nutrition 0.000 claims 1
- 235000015426 Rumex crispus ssp. fauriei Nutrition 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 abstract description 35
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 239000013538 functional additive Substances 0.000 abstract description 2
- 239000005445 natural material Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 102000004388 Interleukin-4 Human genes 0.000 description 10
- 108090000978 Interleukin-4 Proteins 0.000 description 10
- 229940028885 interleukin-4 Drugs 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 240000006439 Aspergillus oryzae Species 0.000 description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 3
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100021752 Corticoliberin Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000005125 Myrtus communis Species 0.000 description 2
- 235000013418 Myrtus communis Nutrition 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- GWNVDXQDILPJIG-YKRBYRBKSA-N (5s,6r,7e,9e,11z,14z)-6-[(2s)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-5-hydroxyicosa-7,9,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-YKRBYRBKSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 235000006467 Camellia japonica Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 102000003858 Chymases Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000988802 Homo sapiens Hematopoietic prostaglandin D synthase Proteins 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000713102 Mus musculus C-C motif chemokine 1 Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001098054 Pollachius pollachius Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 101000885869 Rattus norvegicus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 108010059705 Urocortins Proteins 0.000 description 1
- 102000005630 Urocortins Human genes 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000777 urocortin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
The present invention relates to an antiallergic extract derived from a natural product and a use thereof. More particularly, the present invention relates to an extract of Rumex crispus having an antiallergic effect by blocking secretion of an allergen-inducing substance and a pharmaceutical composition comprising the extract as an active ingredient, Functional foods.
The present invention relates to an antiallergic composition comprising an extract of Rumex crispus as an active ingredient, and more particularly, to an antiallergic composition containing an extract of Rumex crispus as an active ingredient, and more particularly to a method for inhibiting the secretion of an allergen by inhibiting degranulation of mast cells, A pharmaceutical composition for the prevention and treatment of allergic diseases mediated by mast cells or other causes by inhibiting the production of necrotic factor alpha (TNF-a) and interleukin-4 (IL-4) .
When foreign substances come into the body from the outside of the body, an immune reaction that protects our body from these bodies occurs, which is called a normal immune response. However, overexpression of this immune response leads to hypersensitive immune response resulting in somatic abnormality, and a typical disease of such hypersensitive immune response is allergic disease.
The cause of the allergic reaction is caused by the immune system of the human body reacting to external substances acting as allergens, allergens. Allergens are presented on the cell surface by antigen presenting cells, which are recognized by B lymphocytes and converted to plasma cells, releasing antibodies (IgE) that specifically recognize the antigen. Allergic reaction occurs repeatedly in contact with allergens, resulting in an excessive immune reaction to memory cells. IgE binding to the antigen binds to the receptor of mast cells (FcεRI) of the tissues, . The degranulation of mast cells secretes histamine, heparin, leukotrienes, prostaglandine and other anaphylatic agents. These secreted immune activation factors activate the immune system and cause inflammation and allergic reactions.
The reaction is also referred to as immediate hypersensitivity since the antigen appears within one hour after the entry of the antigen. If these acute hypersensitivity reactions are strongly systemic, they are called anaphylaxis, and they can die from suffocation and circulatory disorders. Acute hypersensitivity is mediated by IgE, so the response is antigen-specific. Mast cells are very important in various allergic diseases such as atopic dermatitis, asthma, allergic rhinitis and rheumatoid arthritis. Mast cells play a central role in various physiological, immunological and pathological processes that occur during allergic reactions: wound healing, angiogenesis, host response to parasites and neoplasms, immediate chronic inflammatory response and immediate allergic response to IgE mediated .
The mediators secreted during mast cell activation in allergic reactions include histamine and 5-HT (serotonin), biogenic amines that cause vasodilatation and pain, and IL-1, 4, 6, 10 , 13, MIF, and TNF to induce inflammation and leukocyte migration and proliferation. In addition, by secretion of the phospholipid metabolites leukotrien B4, LTB4, leukotrien C4, LTC4, platelet activating factor (PAF), prostaglandin D2 (prostaglandin D2, PGD2) Leukocyte chemotaxis, airway constriction and pain. In addition, there is a growing interest in the use of enzymes such as chymase and tryptase to induce tissue damage, pain, angiotensin II synthesis, corticotropin-releasing hormone (CRH), endorphin endothelin, kinins, somatostatin substance P, SP, vasoactive intestinal peptide (VIP), urocortin, vascular endothelial growth factor (VEGF) vascular endothelial growth factor (VEGF), and the like, to induce a series of allergic reactions such as inflammation, inflammation, pain, vasodilation, and airway constriction.
The allergic disease drugs developed so far are predominantly antagonistic to histamine and leukotriene receptors secreted by allergens in mast cells. However, since these drugs exhibit tolerance within a short period of time after administration, most of them are used for symptom improvement, and it is not sufficient to prevent the cause of the disease, and serious side effects are caused by medicines.
Also, as a therapeutic method for the treatment of allergic diseases, there is a method of identifying allergens against allergies suffered by allergic patients and administering them in small amounts for several years to gradually reduce the allergen. However, such a treatment has a disadvantage that the treatment period takes several years, and it can cause anaphylactic shock and the like.
In addition, DNA vaccination, the treatment of blocking IgE binding to receptors in mast cells, and the treatment of antibodies against IL-4, an allergen-inducing cytokine, It was not.
Mast cells induce the secretion of several mediators by activation. These signaling pathways occur after allergen forms aggregates with FcεRI, and after coagulation, the Src-family kinase, which is bound to the β-subunit of the receptor The receptor is phosphorylated and signal transduction of the cell begins. Inhibition of Src-family kinase has been shown to inhibit Syk / LAT and its mitogen-activated protein kinase (MAPK) and Akt, and ultimately to inhibit cytokine production and degranulation .
Research on medicinal plants or native plants is actively under way to solve allergic diseases. In particular, there have been studies on the activation signal of mast cells such as Camellia japonica, Corynebacterium glutinosa, Quercus monocytogenes, and Glycyrrhizae extract. In addition, the extracts of Chunghaek and Hojokgang were also found to inhibit allergic response-related intracellular signal transduction. The extracts of Camellia sinensis have been reported to inhibit intracellular signal transduction as Syk specific inhibitors.
Rumex crispus is distributed in Korea, Japan, Taiwan, China, Europe and North Africa. It grows mainly near wetlands and is 30 to 80 cm high. The stem is straight and there are many lines in the vertical, the purple color often on the green background, and the roots become big. Root leaves are long, basal or long elliptical, 10 ~ 25cm long, 4 ~ 10cm long, and the edges are wistful. The stem leaf is alternate, narrow on both ends, wrinkled, and long oval. Flowers bloom in June-July, light green and run in stratum, but the whole is conical. There are six foliage sculptures and stamens, three styles, and the stigma is finely divided like fur. The fruit is achene and is brown. It is surrounded by three pieces of refractory, and the refractory is heart-shaped, with no saw teeth, and there are wart-like projections on the outside. The leaves are edible and the roots are dried. However, the efficacy of extracts from Alzheimer's disease for the treatment and amelioration of allergic diseases is not yet known.
Accordingly, the inventors of the present invention have made efforts to secure a substance capable of treating various allergic diseases without side effects in a fundamental way, and as a result, it has been confirmed that the myrtle extract inhibits the secretion of allergen-inducing substances from mast cells.
On the other hand, prior art related to the antiallergic composition is Korean Patent Laid-Open No. 10-2005-0109958 (composition for antiallergic use), Korean Patent Laid-open No. 10-2009-0088151 (antiallergic or anti- Fermented products).
It is an object of the present invention to provide a method for inhibiting the secretion of allergen-releasing substances secreted from mast cells that cause discomfort to humans or cause various allergic diseases such as atopic dermatitis, allergic rhinitis and asthma, To provide antiallergic materials which are minimized in side effects and maximized in effectiveness.
In order to achieve the above object, the present invention provides a water or alcohol extract of Rumex crispus having an antiallergic effect by blocking secretion of an allergen-inducing substance.
In addition, the present invention provides a pharmaceutical composition for preventing or treating allergic diseases, which comprises, as an active ingredient, a water or alcohol extract of Rumex crispus having an antiallergic effect by blocking secretion of an allergen-inducing substance.
In addition, the present invention provides a health functional food for preventing or alleviating allergies comprising water or an alcohol extract of Rumex crispus having an antiallergic effect by blocking secretion of an allergen-inducing substance.
The present invention also relates to a method for preparing a safflower extract, comprising the steps of: (1) washing and pulverizing a dried Rumex crispus ; and (2) heating the safflower crushed by the step (1) (3) filtering out the syrup extract obtained in the step (2) to obtain a supernatant and concentrating it; And (4) freezing the concentrate obtained in the step (3) and freeze-drying the powder to obtain a powder. The method for producing an extract of Rumex crispus having an antiallergic effect by blocking the secretion of an allergen inducing substance .
In addition, the present invention provides a method for producing an alcoholic extract, comprising the steps of: (1) immersing a dried Rumex crispus in a lower alcohol and extracting it with an ultrasonic extractor to obtain an alcoholic extract; and (2) concentrating the extract obtained from step (1) step; And (3) freezing the concentrate obtained in the step (2) and freeze-drying the powder to obtain a powder. The method for producing an extract of Rumex crispus having an antiallergic effect by blocking secretion of an allergen- .
In accordance with the present invention as described above, the extract of the present invention suppresses the induction of allergy in an animal model of allergenic degranulation (histamine release) action of mast cells inducing allergy at a low concentration, so that the function of suppressing the onset of allergy It is a natural extract that is easy to develop into cosmetics, food and medicine. Therefore, unlike conventional treatment for symptom recovery, it can be usefully used as a selective functional additive for foods and the like as well as cosmetics and medicines whose side effects are minimized by blocking the secretion of allergens in mast cells.
FIG. 1A is a graph showing a concentration-dependent inhibitory effect of the extract of Aspergillus oryzae on the degranulation (histamine secretion) by an allergen-inducing antigen in the RBL-2H3 mast cell which causes allergy to human allergy in the present invention. FIG. 1B shows the results of experiments on the reversibility of the inhibitory effect on mast cell extract mast cells.
FIG. 2 shows the results of inhibiting the inhibition of inflammatory cytokine TNF-α and interleukin-4 (IL-4) expression in mast cells stimulated by antigen.
FIG. 3 shows the results of Western blotting for the functional group of the horseradish extract.
FIG. 4 is a graph showing the inhibitory effect of the mushroom extract according to the present invention on a mast cell-mediated locally allergic animal model.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
Example 1: Preparation of Syrup extract
The present inventors have made a spear extract by using hot water and organic solvent extraction method to obtain spear extract having excellent antiallergic effect.
(1) Hot water extraction method
In order to prepare the hot - water extract of Shiitake, the dried shit - outpastes were washed with distilled water and finely crushed with a grinder. The shredded shrubs were heated in hot water to obtain shrubs extracts. At this time, 1.0 l of water was added to 100 g of the raw material of the shrubs, and the mixture was heated and heated at 100 - 120 ° C for 2 - 3 hours. A cooler was installed to maintain the constant temperature and to prevent the loss of steam. The resulting extract was filtered to obtain a supernatant, which was concentrated using a concentrator. The syrup concentrate was frozen and lyophilized at -80 ° C to prepare an extract powder of Syrup extract.
(2) Organic solvent extraction method
In order to prepare organic solvent extracts of Staphylococcus aureus, fruit or leaves, the spores are immersed in lower alcohol and extracted with an ultrasonic extractor for 2 - 3 weeks to obtain an alcohol extract. Only the supernatant is separated, Respectively. 95% ethanol was used as the alcohol. The alcohol extract obtained by the above process was concentrated using a concentrator, freezed and lyophilized at -80 ° C to prepare an extract powder of a Shigella crassifera extract.
EXPERIMENTAL EXAMPLE 1 Inhibitory Effect of Syrup Extract on Secretion of Allergen-inducing Substances in Mast Cells
The present inventors searched for the suppressive effect of the extract of Alaska pollack extract from Example 1 on the secretion of allergen-inducing substances from mast cells inducing allergy in the body. RBL-2H3 cells were cultured in minimal medium supplemented with glutamine, antibiotics and 15% fetal bovine serum. For secretion experiments, 200,000 cells per well were incubated with 25 ng / ml DNP-specific IgE in a 24-well incubator after collection by trypsin. The next day, cells were washed with PIPES buffer (25 mM PIPES, pH 7.2, 159 mM NaCl, 5 mM KCl, 0.4
Experimental Example 2: Inhibitory effect of the extract of Aspergillus oryzae on the secretion of allergen from mast cells by the antigen (Fig. 1a)
As shown in FIG. 1A, the secretion of allergen from the mast cell mast cells or RBL-2H3 mast cells by the antigens was significantly inhibited at low concentration by the Aspergillus oryzae extract and the secretion was inhibited by more than 50% at 100 μg / ml (Fig. 1A).
Experimental Example 3: Inhibitory effect on cytokine production of mast cell extract on mast cell (Fig. 2)
(TNF-α) and interleukin-4 (IL-4), which are well-known as cytokines secreted from mast cells associated with allergies, have been shown to be specific for each cytokine RT-PCR was performed using primers. First, RBL-2H3 cells stimulated in 6 well plates were lysed with trizol reagent (Invitrogen). Transfer the dissolved sample to a 1.5 ml E-tube, add 200 μl of chloroform, centrifuge at 12,000 g for 20 minutes, mix the supernatant with isopropanol (1: 1) The RNA was precipitated for more than one hour. The RNA was then centrifuged at 12,000 g for 20 minutes to completely precipitate the RNA. The RNA was washed once with ethanol and dissolved in 50 μl of DEPC-water to obtain total RNA. The polymerase chain reaction (PCR) was repeated 30 times at 94 ° C. for 45 seconds, 55 ° C. for 45 seconds, 72 ° C. for 60 seconds. Primer is forward 5'-CAC CAC GCT CTT CTG TCT ACT GAA C-3 ', reverse 5'-CCG GAC TCC GTG ATG TCT AAG TAC T-3', IL-4 is forward 5'- CCG ATT ATG GTGTAA TTT CCT ATG CTG-3 ', reverse 5'-GGC CAA TCA GCA CCT CTC TTC CAG-3', Rat GAPDH forward 5'-GTG GAG TCT ACT GGCGTC TTC- -CCA AGG CTG TGG GCA AGG TCA-3 '.
As a result, as shown in Fig. 2, the production of tumor necrosis factor (TNF-α) and interleukin-4 (IL-4) was almost suppressed at a concentration of 30 ㎍ / The inhibition on the production of cain was evident.
Experimental Example 4. Reversible Effect of Inhibition of Mast cell Activation by the Psoriasis (Fig. 1b)
The inhibitory effect on the degranulation of mast cells was obtained by incubating for 30 minutes before the antigen and then washing the medium with the medium for 5 times before stimulating with the antigen. As shown in FIG. 1b, Granule inhibition was restored. These results suggest that the suppression of the secretion of allergen - inducing substances from mast cells by the antigens of Rhodiola extract is reversible. This inhibition of reversible mast cell degranulation suggested the possibility of preventing side effects of extracts from irreversible nature.
EXPERIMENTAL EXAMPLE 5. Study on the functional action of myrtle extract extract on mast cell (FIG. 3)
The present inventors searched for the inhibitory effect of Syrius extract extracted from Example 1 on activation of Syk-LAT in various signal transduction pathways causing allergic mast cell-induced allergy in the body. RBL-2H3 cells were seeded at a density of 1.0 × 10 6 per well on a 6-well plate and cultured in MEM medium containing 20 ng / ml DNP-specific immunoglobulin E for 12 hours to sensitize the cells. The cells were treated with lysozyme extract for 30 min and then stimulated with antigen. The cells were washed twice with ice-cold PBS, and then lysed in 20 mM HEES, pH 7.5, 150 mM NaCl, 1% Nonidet p-40, 10 mM glycerol, 60 mM octyl- beta -glucoside, 10 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 2.5 mM nitrophenylphosphate, 0.7 μg / ml pepstatin and a protease-inhibitor tablet. Next, centrifugation was carried out at 13,000 rpm for 5 minutes, and the supernatant was mixed with 2x laemmli sample buffer and protein denaturation was performed at 100 ° C for 5 minutes. The protein samples thus obtained were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 120 V for 1 hour and 30 minutes using 10% or 12% polyacrylamide gel (polyacrylamide: bis acrylamide = 29: And transferred to a nitrocellulose membrane (Schleicher & Schuell, BA85) for 1 hour and 30 minutes at 300 mA. The cells were blocked with 5% skim milk or 5% BSA in TBS-T (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20) for one hour and then incubated with each specific antibody Lt; / RTI > Then, HRP (horseradish peroxidase) conjugated monoclonal antibody or polyclonal antibody was allowed to react for one hour, then the remaining nonspecific antibody was washed away with TBS-T, and the X-ray was detected using an ECL detection kit (Amersham Pharmacia Biotech) ray film. As a result, the degree of phosphorylation of Syk and LAT began to decrease at 10 ㎍ / ㎖ of Allium urticae extract, and it was confirmed that protein phosphorylation was suppressed almost at 30 and 100 ㎍ / ㎖.
Experimental Example 6. Detection of antiallergic effect in locally allergic animal model
Balb-c mice 0.5 g of immunoglobulin E was injected intradermally into one ear and sensitized for 12 hours. After 1 hour, 250 μl of the antigen solution (1 mg antigen + 5 mg of Evans blue / ml PBS solution) is injected through the tail vein after oral administration of the shigella extract suspended in 5% arabic gum. After 30 minutes of injection, the mice 'ears were removed and extracted in 700 μl of formamide at 63 ° C for 12 hours. The absorbance at 620 nm of the extracted Evans blue was measured to confirm the antiallergic effect. The results are summarized in FIG.
As shown in FIG. 4, about 50% of the allergic reaction by the antigen was inhibited by about 50% in the group treated with 300 mg / kg, and about 70% was inhibited in the treated group treated with 1,000 mg / kg, Similar effects were seen with lysine drugs. From these results, it can be confirmed that the extract of Aspergillus oryzae according to the present invention exhibits a high inhibitory effect even in an allergic animal model induced by an antigen.
Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (5)
(2) heating the spruce crushed in step (1) in hot water to obtain a spruce extract;
(3) filtering out the syrup extract obtained in the step (2) to obtain a supernatant and concentrating it; And
(4) A method for preparing an extract of Rumex crispus having an antiallergic effect by blocking the secretion of an allergen causing substance, which comprises freezing the concentrate obtained in the step (3) and freeze-drying the powder to obtain a powder.
(2) concentrating the safflower extract obtained in the step (1); And
Curly dock (Rumex crispus) extract method having an anti-allergic effect by blocking the release of allergens including a, (3) obtaining a powder after freeze-drying in which freezing the concentrate according to the above (2).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130163521A KR20150075498A (en) | 2013-12-26 | 2013-12-26 | Rumex crispus extract for allergic diseases and process for preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130163521A KR20150075498A (en) | 2013-12-26 | 2013-12-26 | Rumex crispus extract for allergic diseases and process for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150075498A true KR20150075498A (en) | 2015-07-06 |
Family
ID=53788601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130163521A KR20150075498A (en) | 2013-12-26 | 2013-12-26 | Rumex crispus extract for allergic diseases and process for preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150075498A (en) |
-
2013
- 2013-12-26 KR KR1020130163521A patent/KR20150075498A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102215854B (en) | Extract of aerial parts of oats harvested before ear emergence | |
| RU2671501C1 (en) | Composition containing extract or fraction from justicia plant | |
| KR20110019492A (en) | A composition comprising an extract of cudrania tricuspidata having anti-allergic activity | |
| KR102182724B1 (en) | Antiinflammatory composition comprising Locusta migratoria extract | |
| JP2018516986A (en) | A composition for preventing or treating arthritis comprising an extract of Usubanokiri Moku as an active ingredient | |
| AU2016201841B2 (en) | Medical Composition Containing Stauntonia Hexaphylla Extract | |
| KR101269590B1 (en) | Composition comprising Euphorbia supina extract for preventing and treating inflammentary or allergic disease | |
| KR100912140B1 (en) | Anti-allergy composition comprising leaves extract of Camellia japonica L. | |
| JP7277571B2 (en) | Composition for prevention or treatment of allergic diseases, containing an inotodiol compound as an active ingredient | |
| KR101303383B1 (en) | Composition for inhibiting the degranulation of mast cell comprising plant extracts | |
| KR20150075498A (en) | Rumex crispus extract for allergic diseases and process for preparation thereof | |
| KR20150075497A (en) | Persicaria thunbergii extract for allergic diseases and process for preparation thereof | |
| KR20150074260A (en) | Antiallergic agents comprising extracts from rhamnus davurica | |
| KR20150011075A (en) | Iris netschinskia extract for allergic diseases and process for preparation thereof | |
| KR101849338B1 (en) | A pharmaceutical composition comprising Kaempferol-3-O-rhamnopyranoside or pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of inflammatory diseases, allergic diseases or malaria | |
| KR20160022190A (en) | A composition for the treatment or prevention of asthma comprising erythronium japonicum | |
| KR20170061745A (en) | A pharmaceutical composition comprising anti-allergic peptide isolated from abalone intestine | |
| KR101141191B1 (en) | Functional food composition and pharmaceutical composition for the prevention and alleviation of allergy symptoms | |
| KR20160038102A (en) | Composition for treating, improving or preventing allergic disease containing extract of Triticum aestivum Lamarck | |
| CN107106621B (en) | Pharmaceutical composition for preventing or treating neuroinflammation or neurodegenerative disease comprising Portulaca grandiflora extract or fraction thereof as active ingredient | |
| KR20200069077A (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Apium graveolens hydrolysate as effective component | |
| KR101875317B1 (en) | A pharmaceutical composition comprising costunolide, dehydrocostus lactone, or pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of inflammatory diseases or allergic diseases or malaria | |
| KR20190075850A (en) | A composition for improving, preventing and treating of pruritus comprising Porphyra yezoensis extract | |
| JP5550734B2 (en) | An antiviral composition comprising an extract of Sina brachigiri or pepper, or a fraction thereof as an active ingredient | |
| KR102419683B1 (en) | Asthma relief or therapeutic biologic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |